The US health regulator has given its final approval to Ajanta Pharma for the generic version of its acute migraine pain relief drug Zolmitriptan tablets.

Ajanta Pharma has said in a regulatory filing that “The company received the final approval for Zolmitriptan tablets (2.5 mg, 5 mg) from the US Food and Drug Administration (USFDA). Zolmitriptan is used in the acute treatment of migraine and is a bio-equivalent generic version of Zomig.”

It further added that Zolmitriptan tablets are part of an “ever-growing portfolio” that the company has developed for the US market.

Read EquityPandit’s Nifty Pharma Outlook for this week